Schrödinger and WuXi AppTec Announce the Launch of Faxian Therapeutics to Enable Accelerated Drug Discovery
NEW YORK and SHANGHAI, Oct. 30, 2018 /PRNewswire/ -- Schrödinger Inc, a privately-held company revolutionizing drug discovery through advanced computational methods and enterprise software solutions, and WuXi AppTec, a leading pharmaceutical and medical device R&D enabling platform company, announced today that they have formed Faxian Therapeutics. The new venture will leverage the precision molecular design platforms developed by Schrödinger and accelerate them through partnership with the world-class lead optimization services provided by WuXi AppTec.
Headquartered in New York City, Faxian Therapeutics will identify opportunities where new insights into the chemistry and biology of a particular target and indication can be derived using the Schrödinger computational platform, and then uniquely enabled by integration into a rapid design-synthesize-test cycle implemented at WuXi AppTec.
"We admire WuXi's bold vision that 'every drug can be made and every disease can be treated' and we are excited to join forces with WuXi to make that vision a reality," said Dr. Ramy Farid, Schrödinger's President and CEO. "Faxian Therapeutics is the synergistic pairing of two best‑in‑class companies whose platforms perfectly complement one another; together, we look forward to tackling currently unmet healthcare needs."
"We are thrilled to partner with Schrödinger to create a powerful drug discovery engine running on a virtually-integrated, globally-distributed network," said Mr. Edward Hu, Co-CEO of WuXi AppTec. "By combining the advanced computational platform and expertise in physics-based drug discovery at Schrödinger with the highly efficient chemistry, biology, and DMPK capabilities and technology platforms at WuXi AppTec, we will be able to significantly enable Schrödinger to accelerate new drug discovery and advance new therapies that can potentially improve the health of patients worldwide."
About WuXi AppTec
View original content to download multimedia:http://www.prnewswire.com/news-releases/schrodinger-and-wuxi-apptec-announce-the-launch-of-faxian-therapeutics-to-enable-accelerated-drug-discovery-300739185.html
Company Codes: Shanghai:603259